Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis

Journal of Pathology

Volumn 219, Issue 1, 2009, Pages 16-24

  Marchiò, Caterina ^a,b   Lambros, Maryou B ^a   Gugliotta, Patrizia ^b   Di Cantogno, Ludovica Verdun ^b   Botta, Cristina ^b   Pasini, Barbara ^b   Tan, David S P ^a   Mackay, Alan ^a   Fenwick, Kerry ^a   Tamber, Narinder ^a   Bussolati, Gianni ^b   Ashworth, Alan ^a   Reis Filho, Jorge S ^a   Sapino, Anna ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Amplification; Array CGH; Breast cancer; Centromere; CEP17; HER2; Herceptin; In situ hybridization

Indexed keywords

ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; BREAST CANCER; CENTROMERE; CHROMOSOME 17; CHROMOSOME 17P; CHROMOSOME 17Q; CHROMOSOME MICRODISSECTION; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DISOMY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MICROARRAY ANALYSIS; NUMERICAL CHROMOSOME ABERRATION; ONCOGENE NEU; PRIORITY JOURNAL;

BREAST NEOPLASMS; CENTROMERE; CHROMOSOMES, HUMAN, PAIR 17; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MICROARRAY ANALYSIS; POLYPLOIDY; RECEPTOR, ERBB-2; RECEPTORS, RETINOIC ACID;

EID: 68849111431     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2574     Document Type: Article

References (25)

1. Lambros MB, Natrajan R, Reis-Filho JS. Chromogenic and fluorescent in situ hybridization in breast cancer. Hum Pathol 2007;38:1105- 1122.
2. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-145.
3. Dal Lago L, Durbecq V, Desmedt C, Salgado R, Verjat T, Lespagnard L, et al. Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer. Mol Cancer Ther 2006;5:2572-2579.
4. Ma Y, Lespagnard L, Durbecq V, Paesmans M, Desmedt C, Gomez-Galdon M, et al. Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice. Clin Cancer Res 2005;11:4393-4399.
5. Reddy JC, Reimann JD, Anderson SM, Klein PM. Concordance between central and local laboratory HER2 testing from a community-based clinical study. Clin Breast Cancer 2006;7:153-157.
6. Isola J, Tanner M, Forsyth A, Cooke TG, Watters AD, Bartlett JM. Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization. Clin Cancer Res 2004;10:4793-4798.
7. Arriola E, Marchio C, Tan DS, Drury SC, Lambros MB, Natrajan R, et al. Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines. Lab Invest 2008;88:491-503.
8. Troxell ML, Bangs CD, Lawce HJ, Galperin IB, Baiyee D, West RB, et al. Evaluation of Her-2/neu status in carcinomas with amplified chromosome 17 centromere locus. Am J Clin Pathol 2006;126:709-716.
9. Marchio C, Iravani M, Natrajan R, Lambros MB, Savage K, Tamber N, et al. Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast. J Pathol 2008;215:398-410.
10. Marchio C, Natrajan R, Shiu KK, Lambros MB, Rodriguez-Pinilla SM, Tan DS, et al. The genomic profile of HER2-amplified breast cancers: the influence of ER status. J Pathol 2008;216:399-407.
11. Arriola E, Lambros MB, Jones C, Dexter T, Mackay A, Tan DS, et al. Evaluation of Phi29-based whole-genome amplification for microarray-based comparative genomic hybridisation. Lab Invest 2007;87:75-83.
12. van Beers EH, Joosse SA, Ligtenberg MJ, Fles R, Hogervorst FB, Verhoef S, et al. A multiplex PCR predictor for aCGH success of FFPE samples. Br J Cancer 2006;94:333-337.
13. Coe BP, Ylstra B, Carvalho B, Meijer GA, Macaulay C, Lam WL. Resolving the resolution of array CGH. Genomics 2007;89:647-653.
14. Gunnarsson R, Staaf J, Jansson M, Ottesen AM, Goransson H, Liljedahl U, et al. Screening for copy-number alterations and loss of heterozygosity in chronic lymphocytic leukemia - a comparative study of four differently designed, high resolution microarray platforms. Genes Chromosomes Cancer 2008;47:697-711.
15. Tan DS, Lambros MB, Natrajan R, Reis-Filho JS. Getting it right: designing microarray (and not 'microawry') comparative genomic hybridization studies for cancer research. Lab Invest 2007;87:737-754.
16. Huang J, Gusnanto A, O'Sullivan K, Staaf J, Borg A, Pawitan Y. Robust smooth segmentation approach for array CGH data analysis. Bioinformatics 2007;23:2463-2469.
17. Natrajan R, Lambros MB, Geyer F, Marchiò C, Tan DSP, Vatcheva R, et al. Loss of 16q in high grade breast cancer is associated with oestrogen receptor status: evidence for progression in tumours with a luminal phenotype? Genes, Chromosomes Cancer 2009;48:351-365.
18. Rosenberg CL. Polysomy 17 and HER-2 amplification: true, true, and unrelated. J Clin Oncol 2008;26:4856-4858.
19. Vanden Bempt I, Van Loo P, Drijkoningen M, Neven P, Smeets A, Christiaens MR, et al. Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing. J Clin Oncol 2008;26:4869-4874.
20. Albertson DG. Gene amplification in cancer. Trends Genet 2006;22:447-455.
21. Yeh I-T, Martin MA, Robetorye RS, Gunn S. Polysomy 17 by FISH for HER2 in breast cancer is a misnomer: results of chromosome 17 analysis by array comparative genomic hybridization. Cancer Res 2008;69:207S-207S.
22. Natrajan R, Lambros MB, Rodriguez-Pinilla SM, Moreno-Bueno G, Tan DS, Marchio C, et al. Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin Cancer Res 2009;15:2711-2722.
23. Jarvinen TA, Tanner M, Barlund M, Borg A, Isola J. Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes Chromosomes Cancer 1999;26:142-150.
24. Mano MS, Rosa DD, De Azambuja E, Ismael GF, Durbecq V. The 17q12-q21 amplicon: Her2 and topoisomerase-IIalpha and their importance to the biology of solid tumours. Cancer Treat Rev 2007;33:64-77.
25. Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 2008;358:1409-1411.